149 related articles for article (PubMed ID: 31500970)
21. Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia.
Volc SM; Almeida MT; Abadi MD; Cornacchioni AL; Odone Filho V; Cristofani LM
J Pediatr (Rio J); 2006; 82(6):481-4. PubMed ID: 17003944
[TBL] [Abstract][Full Text] [Related]
22. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children.
Hiltunen M; Hyöty H; Leinikki P; Akerblom HK; Tuomilehto J; Vesikari T
Diabet Med; 1994 Dec; 11(10):942-6. PubMed ID: 7895458
[TBL] [Abstract][Full Text] [Related]
23. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
24. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS
Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764
[TBL] [Abstract][Full Text] [Related]
25. Progress toward measles elimination in Romania after a mass vaccination campaign and implementation of enhanced measles surveillance.
Pistol A; Hennessey K; Pitigoi D; Ion-Nedelcu N; Lupulescu E; Walls L; Bellini W; Strebel P
J Infect Dis; 2003 May; 187 Suppl 1():S217-22. PubMed ID: 12721916
[TBL] [Abstract][Full Text] [Related]
26. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
27. Seroprevalence of Measles, Rubella, Tetanus, and Diphtheria Antibodies among Children in Haiti, 2017.
Minta AA; Andre-Alboth J; Childs L; Nace D; Rey-Benito G; Boncy J; Adrien P; Francois J; Phaïmyr Jn Charles N; Blot V; Vanden Eng J; Priest JW; Rogier E; Tohme RA
Am J Trop Med Hyg; 2020 Oct; 103(4):1717-1725. PubMed ID: 32618256
[TBL] [Abstract][Full Text] [Related]
28. Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.
Izadi S; Zahraei SM; Mokhtari-Azad T
Hum Vaccin Immunother; 2018 Jun; 14(6):1412-1416. PubMed ID: 29420120
[TBL] [Abstract][Full Text] [Related]
29. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
[TBL] [Abstract][Full Text] [Related]
30. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
Kremer JR; Schneider F; Muller CP
Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
[TBL] [Abstract][Full Text] [Related]
31. Serological survey of measles and rubella immunity in Sydney preschool children.
Causer J; Mira M; Karr M; Hueston L; Burgess M; Alperstein G; Fett M; Cunningham A
J Paediatr Child Health; 2000 Oct; 36(5):418-21. PubMed ID: 11036793
[TBL] [Abstract][Full Text] [Related]
32. Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran.
Zahraei SM; Mokhtari-Azad T; Izadi S; Mohammadi M; Sabouri A
Vaccine; 2020 Jan; 38(2):235-241. PubMed ID: 31668816
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
34. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine].
Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L
Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
Leuridan E; Maertens K; Wautier M; Hutse V; Theeten H
Eur J Pediatr; 2015 Jul; 174(7):925-32. PubMed ID: 25579232
[TBL] [Abstract][Full Text] [Related]
36. Progress in measles and rubella elimination in Iran.
Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
[TBL] [Abstract][Full Text] [Related]
37. Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL; Grant GB; Moss WJ; Durrheim DN; Shefer A; Rota PA; Omer SB; Masresha BG; Mulders MN; Hanson M; Linkins RW; Goodson JL
Vaccine; 2019 Sep; 37(38):5745-5753. PubMed ID: 30898393
[TBL] [Abstract][Full Text] [Related]
38. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
Amela C; Pachón I; de Ory F
Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
